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Development of an Ionic Liquid Based Method for the
Preparation of Albumin Nanoparticles
Begüm Demirkurt and Yasar Akdogan*[a]
Albumin based nanocarriers have been widely used in drug
delivery studies. Here, we developed a water-in-ionic liquid (IL)
emulsion-like method to prepare bovine serum albumin (BSA)
nanoparticles as alternative to the traditional organic solvents
containing techniques. Conformational changes of albumin
induced by the imidazolium based ILs at the water-IL interface
triggers the BSA nanoparticle formation. The albumin nano-
particle formation are dependent on the experimental parame-
ters and the hydophobicity of the IL. At pH 9.0, using 1.3%wt of
BSA in water/1-butyl-3-methyl imidazolium tetrafluoroborate
(BmimBF4) (50/50 mol%) and TX-100/butanol surfactant mixture
yields uniformly distributed 200 nm average sized BSA nano-
particles. Different than BmimBF4, using a more hydrophilic IL,
EmimBF4 yielded albumin aggregates. Instead, using a more
hydrophobic IL, HmimBF4 produced albumin nanoparticles but
a non-uniform size distribution was obtained. These results
indicate that the ionic liquids called green and designer
solvents can be also used to synthesize albumin nanoparticles.
Introduction
Nanoparticles have been used as drug carriers for a long time.
Among all possible different nanocarriers, albumin based
nanoparticles have been extensively studied due to their
unique properties such as biodegradability, lack of toxicity and
antigenicity, and easy preparation.[1] Also, high drug binding
capacity of albumin for both hydrophilic and hydrophobic
drugs has inspired scientists to prepare drug nanocarriers from
albumin protein.[2,3] In addition, the albumin nanoparticle is an
attractive candidate for the site-specific delivery of drugs in the
body. The possibility of ligand binding on the surface of
albumin nanoparticles leads to a specific accumulation in the
targeted cells, e.g. tumor cells.[4,5] Also, binding of albumin to
albumin binding proteins, 60kDa glycoprotein (gp60) and
secreted protein, acidic and rich in cysteine, (SPARC) enhances
uptake of albumin nanoparticles by tumors.[6,7]
Formation of albumin nanoparticles is triggered by both
decreasing protein intramolecular interactions and increasing
protein unfolding. Changing the conditions of medium such as
ionic strength, pH, temperature and type of solvent leads to
albumin conformational changes, and thus they may result in
nanoparticle formation. There are two main methods to
prepare albumin nanoparticles; desolvation and emulsification
methods. In the desolvation process, addition of organic
solvents such as ethanol, methanol or acetone reduces the
solubility of the protein in water and leads to nanoparticle
formation under constant stirring.[8,9] In the presence of cross-
linker such as glutaraldehyde, stable albumin nanoparticles
were obtained in the size range of 150–280 nm.[8] Yet, the used
volatile, flammable and toxic organic solvents are harmful for
the environment. Also, the waste of them causes storage
problems.
In the emulsification method, the aqueous solution of
albumin is emulsified in oil phase (castor oil, cyclohexane,
dichloromethane, etc.) by using a high-speed homogenizer,
high-pressure homogenizer or ultrasonic shear.[10–12] Thermal
heating or a cross-linker can be used for the stabilization of the
albumin nanoparticles with the help of surfactants.[10,11] For
example, BSA nanoparticles (600 nm) were synthesized by
using emulsion-heat stabilization technique. The mixture of
basic BSA aqueous solution and castor oil/SPAN-80 was
emulsified by a high-speed homogenizer.[10] In the other study,
BSA aqueous solution was added into cyclohexane/SPAN-80
mixture and then homogenizer was applied to obtain BSA
nanoparticles (400 nm).[11] Also, human serum albumin (HSA)
nanoparticles (130 nm) obtained by emulsification-solvent
evaporation process have been used clinically for the delivery
of paclitaxel, Abraxane® approved by the U.S. Food and Drug
Administration (FDA) in 2005, against breast cancer.[13]
Although, traditional organic solvents have been commonly
used in desolvation and emulsification methods, alternatively,
in this study we used ionic liquids (ILs) to synthesize bovine
serum albumin (BSA) nanoparticle. Ionic liquids are melted salts
with melting points below 100 °C, often below room temper-
ature. Their unique properties have made them alternative
solvents to traditional organic solvents in different fields such
as organic synthesis, catalysis, electrochemistry, purification,
pharmacology, etc.[14,15] Since they are non-volatile, non-flam-
mable and recyclable, they are called green solvents.[16] There-
fore, synthesizing albumin nanoparticles in an IL based system
instead of using organic solvents provides a more environ-
mental friendly synthesizing technique. In addition, physical
properties of ILs such as polarity, miscibility, density and
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viscosity can be tuned by selection different anions and cations.
Therefore, ILs are also referred to as designer solvents.[17]
Serum albumin is a transporter protein for soluble and
insoluble compounds in blood. Several drugs binds to BSA at
two primary binding sites (site I and site II).[18–21] Its globular
structure with three main domains consists of at least 67%
alpha helical structure (Figure 1 (A)).[22] The segments of serum
albumin are connected to each other through hydrogen bonds
and electrostatic or hydrophobic interactions. They may lose
their connections if the interaction to the ILs is favored.
Interactions between ILs and albumin are affected by the kinds
of anions and cations in ILs. For example, imidazolium based
ionic liquids have denaturation effects on the albumin, but
choline based ionic liquid such as choline dihydrogen
phosphate (dhp) has a stabilizing effect on the albumin
structure.[23,24] The denaturing effect of the ILs could be used to
initiate albumin nanoparticle formation. Therefore, the chosen
anions and cations regulate the albumin nanoparticle forma-
tion and affect the physical properties of albumin nanoparticles
such as size, size distribution, morphology and stability. Also,
for drug transportation, especially for the poor water-soluble
drugs, ILs could be very effective to obtain drug loaded
albumin nanoparticles in the future. Different types of drugs
are soluble in ILs depending on the anions and cations.[17] This
could help in encapsulating drugs in the albumin nanoparticle
during the nanoparticle preparation. For these reasons, we aim
to prepare albumin nanoparticles in an IL based system.
In the literature, ionic liquids have been used in emulsion/
microemulsion systems for the replacements of aqueous phase,
oil phase or surfactant molecules.[25] For example, starch nano-
particles were prepared separately in IL/oil, water/IL and water/
oil (IL is surfactant) microemulsion systems.[26–28] Differently, in
this work, we developed an emulsion-like technique by using
imidazolium based ionic liquids to obtain albumin nano-
particles. We chose three 1-alkyl-3-methylimidazolium tetra-
fluoroborate, CnmimBF4, ionic liquids with different alkyl chain
lengths, n=2, 4, and 6: 1-ethyl-3-methylimidazolium tetrafluor-
oborate (EmimBF4), 1-butyl-3-methylimidazolium tetrafluorobo-
rate (BmimBF4) and 1-hexyl-3-methylimidazolium tetrafluorobo-
rate (HmimBF4), respectively (Figure 1 (B)). Increasing the
length of alkyl chain of imidazolium cation increases the
hydrophobicity of the IL.[29,30] This leads to a polar/nonpolar
nanophase separation in the structure of IL. Therefore, addition
of water into ILs that have biphasic structures results in the
water aggregation.[30–34] Here, we showed that mixtures of ILs
and albumin aqueous solution in the presence of surfactants
and glutaraldehyde yield albumin nanoparticles after applying
a high-speed homogenizer in the formed water pools (Fig-
ure 2). Parameters such as pH, BSA concentration, water
volume, glutaraldehyde, surfactant and co-surfactant, and the
effect of alkyl side chain lengths which strongly influence the
BSA nanoparticle formation were studied in detail.
Results and Discussion
In CnmimBF4 ionic liquids with n>4, aggregation of the
hydrophobic alkyl side chains of imidazolium ring leads to a
nanophase separation from ionic domains consisting of the
imidazolium ring and the anion.[30] Therefore, a micelle-like
structure is observed. For the water-IL binary system, polar
water molecules can interact with ionic domains of CnmimBF4.
For example, by addition of water into the BmimBF4, water
molecules are first dissolved and then form water aggregates
around the ionic domains of BmimBF4 especially for the
intermediate water contents (50 mol%).[32–34] Although, these
water rich domains can be investigated by 1HNMR spectro-
scopy,[34] their sizes could not be detected by DLS in here due
to their dynamic and swinging structures. Since the mixture of
CnmimBF4, n>4, and water form unstable mesostructures
composed of water-rich and IL-rich domains, we developed an
emulsion-like method to synthesize albumin nanoparticles in
the water-in-ionic liquid (w/IL) system. For albumin nano-
particle preparation, various experimental parameters and the
effect of alkyl side chains of ILs were studied in detail.
Figure 1. (A) Crystal structure of bovine serum albumin (BSA) (pdb-ID:
3v03).[22] (B) Chemical structures of imidazolium based ionic liquids (ILs):
EmimBF4, BmimBF4 and HmimBF4.
Figure 2. Schematic representation of BSA nanoparticle synthesis using
water-in-IL emulsion-like technique.
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Effect of pH value on the albumin nanoparticle formation
The influence of aqueous phase pH value on the nanoparticle
formation was studied with three different pH values including
pH 4.0, 7.0 and 9.0. First, 12 mg of BSA aqueous solution (with
glutaraldehyde) in 285 μL water was prepared at pH 4.0 and
then mixed with BmimBF4 solution in the presence of
surfactant (TX-100) and co-surfactant (1-butanol). After that,
high speed homogenizer was applied to obtain BSA nano-
particles. But, at pH 4.0, BSA aggregation was observed. SEM
image of this aggregation was shown in Figure S1 (A). Next,
BSA aqueous solution was prepared at pH 7.0 and then mixed
with BmimBF4. After following the same procedure, a limited
number of BSA nanoparticles in a film-like BSA structure was
detected in the SEM images (Figure S1 (B) and (C)).
On the other hand, further increasing the pH value of BSA
solution to 9.0, and then mixing with BmimBF4 yielded BSA
nanoparticles with regular spherical shapes (Figure 3 (A) and
(B)). Figure 3 (C) shows the particle size distribution obtained
from the SEM image in Figure 3 (A). The average size of
albumin nanoparticles is 330 nm with a size distribution
between 150 and 600 nm. In addition, DLS provides their
average size as around 520 nm in solution with a PDI 0.271
(Figure S2 (A)). Also, the zeta potential of the BSA nanoparticles
was found as   11 mV. Obtaining higher average particle size in
solution by DLS is reasonable due to the formation of hydration
shell and/or swelling nanoparticles with water.
These observations are in good agreement with the earlier
works in which smaller albumin nanoparticles were obtained at
pH 8.0 - 9.0 with the desolvation technique.[8,35] The influence of
pH on the isolated albumin nanoparticle formation can be
explained by the charge effects. Although, the structure of
albumin remains stable between pH values of 4.0 and 9.0, the
charge of albumin changes from positive to negative with
reported isoelectric points in the range from 4.8 to 5.6.[36] At
pHs 4.0, 7.0 and 9.0, the reported charges of BSA are +10,   13,
and   26, respectively.[36] The absolute value of charge of BSA at
pH 9.0 is about twice the absolute value of charges of BSA at
pH 4.0 and 7.0. Therefore, higher electrostatic repulsive forces
at pH 9.0 keep the formed albumin nanoparticles away from
each other which avoids the agglomeration. In addition, the
albumin nanoparticle formation can be affected by the types of
intermolecular interactions between BmimBF4 and BSA which
are also pH dependent. In addition to hydrogen bonding and
hydrophobic interactions which exist between [Bmim]+ and
BSA, a higher electrostatic attraction between [Bmim]+ and
BSA takes place at pH 9.0 due to a net higher negative charge
on albumin. At pH 9.0, the combination of these forces possibly
supports the albumin nanoparticle formation and stabilization.
Effect of BSA concentration on the albumin nanoparticle
formation
Effect of BSA concentration (in 285 μL water, at pH 9.0) on the
size of BSA nanoparticles was studied with 0.5, 4 and 12 mg of
BSA. Addition of 12 mg BSA (0.6 mM, 4 wt% in water)
containing water into BmimBF4 yielded BSA nanoparticles
(average 330 nm) with a size distribution between 150 and
600 nm (Figure 3). In order to obtain smaller nanoparticles with
a narrower size distribution, we decreased the BSA content
from 12 mg to 4 mg (0.2 mM, 1.3 wt% in water). As a result,
BSA nanoparticles of 200 nm average size with a size distribu-
tion between 100 and 300 nm was obtained (Figure 4). In
addition, DLS provided their average size as around 450 nm in
solution with a PDI 0.175 (Figure S2 (B). The sizes obtained
from DLS are larger compare to the results obtained from SEM
image, just like the results of sample obtained with 12 mg of
BSA.
Lomis et al. showed that decreasing the BSA concentration
in chloroform/water solution yields smaller BSA nanoparticles
in the emulsion-solvent evaporation method.[2] Decreasing the
BSA concentration leads to a decrease in the BSA-BSA
Figure 3. (A, B) SEM images of BSA nanoparticles prepared by addition of
12 mg BSA aqueous solution (285 μL) at pH 9.0 to the BmimBF4 (3 g) based
system. (C) Particle size distribution obtained from the SEM image (A). Final
BSA concentration is 0.06 mM. Mol% of water and BmimBF4 are 53% and
44%, respectively.
Figure 4. (A) SEM image of BSA nanoparticles prepared by addition of 4 mg
of BSA aqueous solution (285 μL) at pH 9.0 to the BmimBF4 (3 g) based
system. (B) Particle size distribution obtained from the SEM image (A). Final
BSA concentration is 0.02 mM. Mol% of water and BmimBF4 are 53% and
44%, respectively.
Full Papers
9942ChemistrySelect 2018, 3, 9940–9945 © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Donnerstag, 13.09.2018
1834 / 120513 [S. 9942/9945] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
interactions. This avoids the formation of larger particles or
agglomeration of BSA clusters. Also, BSA concentration directly
affects the microviscosity of the system. Increasing the micro-
viscosity in the nanodroplets with higher BSA concentration
may cause additional resistance against applied shear stress
during high-speed homogenization. This may hinder smaller
nanodroplet formation. On the other hand, further decreasing
the BSA content to 0.5 mg (0.025 mM, 0.16 wt%) in water did
not yield albumin nanoparticles (Figure S3). A film-like forma-
tion was detected. This could be originated from the
insufficient numbers of BSA to interact with and support to
each other.
Effect of water volume on the albumin nanoparticle
formation
BmimBF4 is a hydrophilic ionic liquid, and it is macroscopically
miscible with water at any concentrations. However, their
mixtures are not homogeneous on the microscopic scale
especially for the intermediate water contents (50 mol%).[34]
Above the critical aggregation concentration (CAC=0.45 M) of
BmimBF4, unstable mesostructures composed of water-rich and
IL-rich domains were obtained.[31–33] Therefore, increasing the
water content in BmimBF4 phase produces water aggregates/
pools. In Figure 3, we showed that 285 μL of water (53% mol)
was used to solve BSA and then mixed with 3 g of BmimBF4
(4.5 M, 44% mol) to obtain BSA nanoparticles.
However, dissolving the same amount of BSA (12 mg) in
less or more water phase gave different results. Figure 5 (A)
and (B) show the SEM images of BSA samples obtained upon
addition of 165 μL (40% mol) and 525 μL (67% mol) of BSA
containing water solutions into 3 g of BmimBF4, respectively. In
Figure 5 (A), mostly insoluble albumin aggregates were
observed when 165 μL water (40% mol) was used. By
decreasing the water content from 285 μL (53% mol) to 165 μL
(40% mol), BSA concentration increases from 0.6 mM to 1.1 mM
since 12 mg of BSA used for both conditions. It seems that
during the albumin nanoparticle formation, close interactions
between BSA proteins turned into larger aggregates with the
help of glutaraldehyde cross linking process. On the other
hand, by keeping the BSA amount constant, increasing the
volume of water phase from 285 μL (53% mol) to 525 μL (67%
mol) produced larger BSA nanoparticles with non-uniform size
distributions (Figure 5 (B)). This can be explained by the
formation of larger water aggregates with increasing the water
content. Also, applying the homogenizer with the same speed
and time to a higher volume of water contained system might
not be energetically successful to lead small nanoparticles with
uniform size distributions.
Effects of using glutaraldehyde and surfactants on the
albumin nanoparticle formation
As a cross-linker glutaraldehyde has been used mostly to
stabilize the formed albumin nanoparticles.[8] It can cross-link
proteins through amino acids with free amine sites such as
lysine. Here, glutaraldehyde is required to stabilize the
prepared albumin nanoparticles too. Without glutaraldehyde,
albumin proteins form aggregates upon mixing with BmimBF4
in the emulsion-like system (Figure S4). This shows the
importance of using glutaraldehyde as cross-linker in this
system to obtain stable albumin nanoparticles.
Furthermore, effects of surfactant (TX-100) and co-surfac-
tant (1-butanol) on the albumin nanoparticle synthesis were
studied. Surfactant molecules can decrease the interfacial
tension between immiscible liquids in a system. This increases
miscibility, colloidal stability and dispersion of nanoparticles in
liquid.[34] In our system, BSA nanoparticle formation was not
achieved without TX-100 and 1-butanol. As already shown in
Figure 3 and 4, using 50 mM of non-ionic surfactant TX-100
(with 140 mM of 1-butanol) below its critical micelle concen-
tration (CMC)[37] in BmimBF4 helped to obtain BSA nano-
particles. Besides, using higher amount of surfactants such as
125 mM of TX-100 (with 420 mM of 1-butanol) caused BSA
aggregation (Figure S5 (A)). Behera et al. showed that the CMC
value of TX-100 increases with BmimBF4 concentration in the
aqueous solution.[37] At 30 wt% of BmimBF4 solution, TX-100
does not form aggregation up to 50 mM of TX-100.[37] There-
fore, in here, it is not expected to observe TX-100 (50 mM)
aggregation in the 85 wt% of BmimBF4 aqueous solution. But,
125 mM of TX-100 may form aggregation in our system and
may cause the coalescence of BSA nanoparticles. This shows
that the ratio of surfactants in the system plays a significant
role for the BSA nanoparticle formation. In addition, Figure S5
(B) shows the role of the co-surfactant 1-butanol in this system.
1-butanol molecules may have aligned on the interface of the
water/IL along with the TX-100 molecules and thus they
enhanced water solubility of the obtained nanoparticles. There-
fore, BSA aggregation was observed without using 1-butanol in
the system (Figure S5 (B)).
Effects of alkyl chain lengths of ILs on the albumin
nanoparticle formation
Structures of ILs-water mixtures are strongly dependent on the
choice of the anion and cation. BF4
  ion containing imidazo-
lium based ILs show hydrophilic properties, and their hydro-
philicity decreases with increasing the alkyl chain lengths of
Figure 5. SEM images of BSA samples prepared by addition of 165 μL (A) and
525 μL (B) of BSA (12 mg) aqueous solutions to the BmimBF4 based systems.
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the imidazolium ring.[38] Therefore, in IL-water mixture, water
pool formation increases with longer alkyl chain of IL. In
addition, imidazolium types of ILs have denaturation effect on
the albumin structure. Increasing the alkyl side chain of
imidazolium cations leads to a higher albumin unfolding due
to the enhanced hydrophobic interactions.[23] Here, we studied
three imidazolium based ionic liquids (EmimBF4, BmimBF4 and
HmimBF4) with different alkyl chain lengths to obtain albumin
nanoparticles. Addition of 4 mg BSA solution (285 μL water)
into 3 g of EmimBF4 in the presences of glutaraldehyde and
surfactants did not produce BSA nanoparticles after applying
the high-speed homogenizer. Figure 6 (A) shows the SEM
image of BSA aggregates obtained by using EmimBF4. As
already shown in Figure 3 and 4, BSA nanoparticles can be
obtained in the BmimBF4 based system. Increasing the alkyl
side chain of imidazolium cation favors the polar/nonpolar
nanophase separation in ILs. Therefore, water molecules can be
aggregated in the polar regions of BmimBF4 which stimulate
the nanoparticle formation. Since the hydrophobicity of ethyl
groups is not strong enough to create robust nonpolar
domains in IL, water molecules can be homogeneously
distributed in EmimBF4 more than in BmimBF4. Thus, they do
not form water pools extensively in EmimBF4 which are
necessary for the albumin nanoparticle formation.
Further increasing the length of alkyl side chain of
imidazolium cation from butyl to hexyl, water solubility
decreases. Thus, this leads to larger water pools formation
around the polar regions of HmimBF4. Addition of 4 mg BSA
solution (285 μL water) into 3 g of HmimBF4 in the presences of
glutaraldehyde and surfactants produce BSA nanoparticles after
applying the high-speed homogenizer (Figure 6 (B)). As
expected, larger water pools formed in the water-HmimBF4
system leaded to the larger BSA nanoparticles compared to
those formed in the water-BmimBF4 system. Spherical BSA
nanoparticles with a broad size distribution between 0.2 μm
and 1.2 μm were obtained in the water-HmimBF4 micro-
emulsion like system.
Conclusions
Organic solvents have been commonly used to prepare
albumin nanoparticles. However, ionic liquids have been
considered as green replacements for organic solvents due to
their unique properties in addition to their designability
features. Therefore, alternatively, here an imidazolium based
ionic liquid of BmimBF4 was used to prepare albumin nano-
particles.
It has been known that water in BmimBF4 at intermediate
levels (e.g. 50 mol%) forms water aggregates/pools.[31–34] These
water aggregates are strongly dependent on the alkyl chain
length of the imidazolium cation. Increasing the alkyl chain
length forms larger water pools in the water-IL binary mixtures.
Here, addition of BSA aqueous solution with glutaraldehyde
into BmimBF4 (with TX-100 and 1-butanol) forms an emulsion-
like system upon applying high-speed homogenizer. Interac-
tions between BmimBF4 and BSA at the water/BmimBF4 inter-
face denature the BSA. After that, high-speed homogenization
converted denatured BSA into BSA nanoparticles with the help
of glutaraldehyde (Figure 2). By choosing the right experimen-
tal parameters including the pH value, concentration of BSA,
volume of water solution and surfactant/co-surfactant ratios,
smaller BSA nanoparticles (200 nm) with uniform size distribu-
tion can be obtained. Furthermore, using an IL with a shorter
alkyl chain such as EmimBF4 did not yield BSA nanoparticles,
but using an IL with a longer alkyl chain, HmimBF4, produced
larger BSA nanoparticles with a broad size distribution. In more
hydrophobic CnmimBF4 ionic liquids with n=4 and 6, water
pools were created upon addition of water at an intermediate
level, which help nanoparticle formation. This shows the
importance of water pools formation in the water-IL system for
the BSA nanoparticle preparation. Here, we showed that ionic
liquids can be good candidates for use in the preparation of
albumin nanoparticles. The developed method is, of course,
not restricted to bare albumin nanoparticle formation, could be
applied to the field of drug loaded nanoparticles in the further
studies.
Supporting Information Summary
Experimental details are given in the supporting information.
Table S1 summarized the sample preparation. SEM images and
DLS results were given in Figure S1 - S5.
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Figure 6. (A) SEM image of BSA aggregates obtained by using EmimBF4 and
(B) SEM image of BSA nanoparticles obtained by using HmimBF4. 4 mg of
BSA aqueous solution (285 μL) at pH 9.0 was added to the ILs (3 g) based
system. Final BSA concentration is 0.015 mM. Mol% of water and ILs are 53%
and 44%, respectively.
Full Papers
9944ChemistrySelect 2018, 3, 9940–9945 © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Donnerstag, 13.09.2018
1834 / 120513 [S. 9944/9945] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
Keywords: Albumin nanoparticles · drug carrier · emulsion ·
ionic liquids
[1] A. O. Elzoghby, W. M. Samy, N. A. Elgindy, J. Control. Release 2012, 157,
168–182.
[2] N. Lomis, S. Westfall, L. Farahdel, M. Malhotra, D. Shum-Tim, S. Prakash,
Nanomaterials 2016, 6, (116), 1–17.
[3] X. Tang, G. Wang, R. Shi, K. Jiang, L. Meng, H. Ren, J. Wu, Y. Hu, Drug
Deliv. 2016, 23, 2686–2696.
[4] L. Zhang, S. Hou, S. Mao, D. Wei, X. Song, Y. Lu, Int. J. Pharm. 2014, 287,
155–162.
[5] J. S. Choi, N. Meghani, Colloids Surf. B Biointerfaces 2016, 145, 653–661.
[6] N. Desai, V. Trieu, Z. Yao, L. Louie, S. Ci, A. Yang, C. Tao, T. De, B. Beals, D.
Dykes, P. Noker, R. Yao, E. Labao, M. Hawkins, P. Soon-Shiong,
Clin.Cancer Res. 2006, 12, 1317–1324.
[7] K. Komiya, T. Nakamura, C. Nakashima, K. Takahashi, H. Umeguchi, N.
Watanabe, A. Sato, Y. Takeda, S. Kimura, N. Sueoka-Aragane, Onco.
Targets Ther. 2016, 9, 6663–6668.
[8] K. Langer, S. Balthasar, V. Vogel, N. Dinauer, H. Von Briesen, D. Schubert,
Int. J. Pharm. 2003, 257, 169–180.
[9] B. Von Storp, A. Engel, A. Boeker, M. Ploeger, K. Langer, J. Microencapsul.
2012, 29, 138–146.
[10] L. Yang, F. Cui, D. Cun, A. Tao, K. Shi, W. Lin, W. , Int. J. Pharm. 2007,
340, 163–172.
[11] F. Crisante, I. Francolini, M. Bellusci, A. Martinelli, L. D’Ilario, A. Piozzi, Eur.
J. Pharm. Sci. 2009, 36, 555–564.
[12] Q. Zhang, L. Zhang, L. Zemin, X. Xie, X. Gao, X. Xu, AAPS Pharm. Sci. Tech.
2017, 18, 2977–2986.
[13] N. Desai, Nanoparticle Albumin-Bound Paclitaxel (Abraxane®). In: M.
Otagiri, V. Chuang (eds) Albumin in Medicine. 2016, Springer,
Singapore.
[14] Z. Qiu, J. Texter, Curr. Opin. Colloid Interface Sci. 2008, 13, 252–262.
[15] K. Ghandi, Green Sustain. Chem. 2014, 4, 44–53.
[16] S. Goindi, R. Kaur, R. Kaur, Int. J. Pharm. 2015, 495, 913–923.
[17] N. Adawiyah, M. Moniruzzaman, S. Hawatulaila, M. Goto, Med. Chem.
Comm. 2016, 7, 1881–1897.
[18] J. Ghuman, P. A. Zunszain, I. Petitpas, A. A. Bhattacharya, M. Otagiri, S.
Curry, J. Mol. Biol. 2005, 353, 38–52.
[19] F. Yang, C. Bian, L. Zhu, G. Zhao, Z. Huang, M. Huang, J. Struct. Biol.
2007, 157, 348–355.
[20] D. Tatlidil, M. Ucuncu, Y. Akdogan, Phys. Chem. Chem. Phys. 2015, 17,
22678–22685.
[21] Y. Akdogan, M. Emrullahoglu, D. Tatlidil, M. Ucuncu, G. Cakan-Akdogan,
Phys. Chem. Chem. Phys. 2016, 18, 22531–22539.
[22] K. A. Majorek, P. J. Porebski, A. Dayal, M. D. Zimmerman, K. Jablonska,
A. J. Stewart, M. Chruszcz, W. Minor, Mol. Immunol. 2012, 52, 174–182.
[23] Y. Akdogan, M. J. N. Junk, D. Hinderberger, Biomacromolecules 2011, 12,
1072–1079.
[24] Y. Akdogan, D. Hinderberger, J. Phys. Chem. B 2011, 115, 15422–15429.
[25] J. Kuchlyan, N. Kundu, N. Sarkar, Curr. Opin. Colloid Interface Sci. 2016,
25, 27–38.
[26] G. Zhou, Z. Luo, X. Fu, J. Agric. Food Chem. 2014, 62, 8214–8220.
[27] G. Zhou, Z. Luo, X. Fu, Ind. Crops Prod. 2014, 52, 105–110.
[28] X. Wang, H. Chen, Z. Luo, X. Fu, Carbohydr. Polym 2016, 138, 192–200.
[29] T. Mendez-Morales, J. Carrete, O. Cabeza, L. J. Gallego, L. M. Varela, J.
Phys. Chem. B 2011, 115, 6995–7008.
[30] Y. Akdogan, J. Heller, H. Zimmermann, D. Hinderberger, Phys. Chem.
Chem. Phys. 2010, 12, 7874–7882.
[31] B. Wu, L. Zhang, Y. M. Zhang, H. P. Wang, Chem. Eur. J. 2009,
doi:10.1002/chem.200901098.
[32] D. R. Kattnig, Y. Akdogan, I. Lieberwirth, D. Hinderberger, Mol. Phys.
2013, 111, 2723–2737.
[33] D. R. Kattnig, Y. Akdogan, C. Bauer, D. Hinderberger, Z. Phys. Chem.
2012, 226, 1363–1378.
[34] K. Saihara, Y. Yoshimura, S. Ohta, A. Shimizu, Sci. Reports 2015, 5, 10619.
[35] S. Sebak, M. Mirzaei, M. Malhotra, A. Kulamarva, S. Prakash, Int. J.
Nanomed. 2010, 5, 525–532.
[36] L. R. S. Barbosa, M. G. Ortore, F. Spinozzi, P. Mariani, S. Bernstorff, R. Itri,
Biophys. J. 2010, 98, 147–157.
[37] K. Behera, M. D. Pandey, M. Porel, S. Pandey, J. Chem. Phys. 2007, 127,
184501.
[38] H. Heinz, C. Pramanik, O. Heinz, Y. Ding, R. K. Mishra, D. Marchon, R. J.
Flatt, I. Estrela-Lopis, J. Llop, S. Moya, R. F. Ziolo, Surf. Sci. Rep. 2017, 72,
1–58.
[39] S. Feng, G. A. Voth, Fluid Phase Equilib. 2010, 294, 148–156.
Submitted: May 30, 2018
Accepted: September 6, 2018
Full Papers
9945ChemistrySelect 2018, 3, 9940–9945 © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Wiley VCH Donnerstag, 13.09.2018
1834 / 120513 [S. 9945/9945] 1
